{
  "abstract": "Background Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated significant benefits in reducing cardiovascular events in patients with type 2 diabetes mellitus (T2DM) and established coronary artery disease (CAD). Guidelines from the National Institute for Health and Care Excellence (NICE) and the European Society of Cardiology (ESC) recommend the use of SGLT2i in this high-risk population. This audit examines compliance with these guidelines in a clinical setting.Aim To evaluate adherence to the National Institute for Health and Care Excellence (NICE) and the European Society of Cardiology (ESC) guidelines regarding the prescription of Sodium-glucose cotransporter 2 inhibitors (SGLT2i) in diabetic patients with coronary artery disease (CAD), to identify barriers to guideline compliance, and to highlight areas for improvement.Methods A retrospective audit was conducted on diabetic patients with coronary artery disease (CAD), who were managed from February 2024 to May 2024. Patient data were extracted from electronic health records, focusing on the prescription of Sodium-glucose cotransporter 2 inhibitors (SGLT2i), patient demographics, clinical outcomes, and reasons for non-compliance. Compliance was measured against the criteria outlined in the National Institute for Health and Care Excellence (NICE) and the European Society of Cardiology (ESC) guidelines. Descriptive statistics and comparative analyses were performed.Results Out of 171 patients whose invasive angiograms confirmed coronary artery disease (CAD), 59 (34.5%) met our inclusion criteria. Among these 59 patients, 12 (20.3%) were initiated on Sodium-glucose cotransporter 2 inhibitors (SGLT2i), 18 (30.5%) were already on Sodium-glucose cotransporter 2 inhibitors (SGLT2i) therapy, and 29 (49.2%) were not prescribed Sodium-glucose cotransporter 2 inhibitors (SGLT2i).Conclusion Despite their proven efficacy, there remains a gap in the initiation of Sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus patients with evidence of coronary artery disease. This gap in compliance highlights the need for continued education and addressing barriers to optimize the use of glucose cotransporter 2 inhibitors in this population.",
  "authors": [
    {
      "affiliations": [
        "University Hospital Southampton, Tremona Road, Southampton, SO16 6YD, UK"
      ],
      "name": "Mahmoud Hani"
    },
    {
      "affiliations": [
        "University Hospital Birmingham, Mindelsohn Way, Birmingham, B15 2GW, UK"
      ],
      "name": "Mohamed Abdou"
    }
  ],
  "title": "P21 Compliance with sodium-glucose cotransporter 2 inhibitors (SGLT2i) prescribing guidelines for diabetic patients with atherosclerotic cardiovascular disease: insights from Cath lab",
  "uid": "c5f4d93f-f97a-5847-a3f8-e3a5636054bc"
}